Skip to main content
Home > BioCentury on BioBusiness > Strategy

Chronological Index of : Strategy

 Current Issue
  • Pfizer's growth spurt

    How Allergan would fit with Pfizer

    Pfizer has created its own growth story over the last 18 months, making a takeout of Allergan more an amenity than a necessity.

    Published on 11/9/2015
  • Box: Establishing the business

    Pfizer's growth spurt Establishing the business Pfizer Inc.'s established pharma business includes drugs that are generic or will be by the end of 2015, as well as biosimilars and sterile injectables. Revenues …

    Published on 11/9/2015
  • Figure: Growth potential

    Pfizer's growth spurt Growth potential Since last year’s aborted attempt to acquire AstraZeneca plc (LSE:AZN; NYSE:AZN), Pfizer Inc. (NYSE:PFE) has increased top- and bottom-line growth rates through acquisition …

    Published on 11/9/2015
  • Figure: Pfizer's pipeline progress

    Pfizer's growth spurt Pfizer’s pipeline progress In the last 18 months, Pfizer Inc. (NYSE:PFE) has gotten three new products approved and advanced 10 other late-stage programs to the next phase of development or …

    Published on 11/9/2015
  • Three's company

    How NCCN determines affordability in new cancer drug value framework

    NCCN's new tool for assessing drug values juxtaposes efficacy and safety benefits against oncologists' subjective assessment of affordability, rather than price.

    Published on 11/2/2015
  • Table: Variations on value

    Three's company Variations on value The National Comprehensive Cancer Network (NCCN), the American Society of Clinical Oncology (ASCO) and Memorial Sloan Kettering Cancer Center (MSKCC) have each developed tools …

    Published on 11/2/2015
  • Zai's second act

    Why China in-licensing play Zai built a discovery research center

    With a new R&D center, China's Zai expands from a pure in-licensing play into a globally minded R&D house.

    Published on 11/2/2015
  • Figure: Zai's discovery center

    Zai's second act Zai's discovery center Zai Laboratory Ltd.'s new 10,000-square-foot R&D facility in the Zhangjiang Hi-Tech Park in Shanghai will allow the biotech to expand into discovery of novel proteins and …

    Published on 11/2/2015
  • Figure: Pipeline updates

    Against the wind Pipeline updates Following setbacks for two Phase III programs in multiple sclerosis, Biogen Inc. (NASDAQ:BIIB) now has a pipeline more heavily weighted toward Alzheimer's disease and other …

    Published on 10/26/2015
  • Figure: Slowing growth

    Against the wind Slowing growth Biogen Inc. (NASDAQ:BIIB) had seen steady revenue and EPS growth during the first few years of George Scangos' tenure as CEO, which began in July 2010; however, growth has flattened…

    Published on 10/26/2015
  • Figure: Tecfidera tumble

    Against the wind Tecfidera tumble Shares of Biogen Inc. (NASDAQ:BIIB) have tumbled 42% since their 52-week high on March 20 amid disappointing results for Tecfidera dimethyl fumarate and a broad biotech sell-off. …

    Published on 10/26/2015
  • Table: Roche's cancer immunotherapy deals

    Collaborating on combos Roche's cancer immunotherapy deals Roche (SIX:ROG; OTCQX:RHHBY) has done 13 deals to gain access to candidates for cancer immunotherapy combinations with its atezolizumab, a mAb against PD-…

    Published on 10/26/2015
  • Against the wind

    How Biogen plans to restore Tecfidera sales and find its future growth arc

    Biogen's MS woes leave it dependent on investors' willingness to wait for key data on high-risk, high-reward growth drivers.

    Published on 10/26/2015
  • Collaborating on combos

    How Roche is thinking about cancer immunotherapy combinations

    Roche has breached the walls between gRED and pRED to decide which cancer immunotherapy combinations to develop using its own and collaborators' molecules.

    Published on 10/26/2015
  • Preferring PCSK9s

    How payers, PBMs are using ICER's analyses in PCSK9 coverage decisions

    As ICER continues to refine its analysis of PCSK9 inhibitors, payers and PBMs are making their choices for the lipid-lowering drugs.

    Published on 10/19/2015
  • Sourcing biologics in China

    Why Lilly went back for second biologics deal with China's Innovent

    Why Lilly went back for a second biologics deal with China's Innovent.

    Published on 10/19/2015
  • Figure: Getting (Bi)specific

    Dual duty Getting (Bi)specific Structures of (A) bispecific antibodies against CD3 and CD38 produced by the Xencor Inc. (NASDAQ:XNCR) platform and (B) Blincyto blinatumomab produced by the Amgen Inc. (NASDAQ:AMGN)…

    Published on 9/21/2015
  • Dual duty

    Xencor deal gives Amgen more advanced MM program, second bispecific platform

    Amgen tapped Xencor for a more advanced anti-CD38 bispecific for myeloma and the chance to pit BiTEs against an alternative platform.

    Published on 9/21/2015
  • Mind melding

    How Novartis and Amgen crafted a multi-asset swap to spread risk in neurology

    Novartis' multi-asset deal with Amgen spreads risk across a beefed-up neurology portfolio and adds to near-term launches.

    Published on 9/14/2015
  • Table: Novartis' neurology expansion

    Mind melding Novartis' neurology expansion The acquisition of Spinifex Pharmaceuticals Pty Ltd. and deals with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Amgen Inc. (NASDAQ:AMGN), shaded below, will help Novartis…

    Published on 9/14/2015
  • Changing the subject

    23rd BioCentury Back to School Issue: Let patients show the way in drug development

    As 'value' becomes the rallying cry of payers, the 23rd Back to School essay says industry must help patients show the way throughout the product life cycle.

    Published on 9/7/2015
  • Box: Academy for advocacy

    Changing the subject Academy for advocacy The European Patients' Academy on Therapeutic Innovation is providing patients with formal training about drug development and regulatory and reimbursement decisions with …

    Published on 9/7/2015
  • Box: CDRH: Preferences in action

    Changing the subject CDRH: Preferences in action FDA's Center for Devices and Radiological Health established an important precedent when it used patient preference data to approve the Maestro Rechargeable System …

    Published on 9/7/2015
  • Box: Chartered territory

    Changing the subject Chartered territory UCB Group and the Parkinson's Disease Foundation are developing a charter to align their expectations, goals and work plan for a new company-patient collaboration, which …

    Published on 9/7/2015
  • Box: Convincing payers

    Changing the subject Convincing payers Anthem Inc.'s HealthCore Inc. subsidiary has been working directly with patients for more than eight years to get feedback on endpoints that are important to them and to …

    Published on 9/7/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993